44 filings
8-K
SWTX
SpringWorks Therapeutics Inc
27 Feb 24
Entry into a Material Definitive Agreement
8:28am
8-K
SWTX
SpringWorks Therapeutics Inc
27 Feb 24
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
6:44am
8-K
SWTX
SpringWorks Therapeutics Inc
2 Feb 24
Departure of Directors or Certain Officers
4:01pm
8-K
SWTX
SpringWorks Therapeutics Inc
6 Dec 23
SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock
4:10pm
8-K
SWTX
SpringWorks Therapeutics Inc
28 Nov 23
SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
9:00am
8-K
z0fiaxi910wbe8
17 Nov 23
SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN
7:00am
8-K
ok0 cr55nut
2 Nov 23
SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
6:35am
8-K
dp72910eqj 2k5c2
1 Sep 23
Departure of Directors or Certain Officers
4:01pm
8-K
jxh7gyaainn
2 Aug 23
SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
6:33am
8-K
htb78 32d6mowd0fkqbh
5 Jun 23
SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDA
6:57am
8-K
5kzqd 90w4ro7
25 May 23
Submission of Matters to a Vote of Security Holders
4:08pm
8-K
o5lnq2w8ujulp1v8
3 May 23
SpringWorks Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
6:35am
8-K
yky5jdaadg
10 Mar 23
Regulation FD Disclosure
5:23pm
8-K
9rpo7zd 7tq6nv4mwe0a
28 Feb 23
SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights
6:37am
8-K
xvfb2wb
3 Nov 22
SpringWorks Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
6:36am
8-K
pcs8gbcp gdcbbqfcy
16 Sep 22
Departure of Directors or Certain Officers
4:30pm
8-K
5qpcy
12 Sep 22
Other Events
6:02am
8-K
a748p
8 Sep 22
Entry into a Material Definitive Agreement
4:01pm
8-K
t87wb 59nmn143c
7 Sep 22
Entry into a Material Definitive Agreement
4:40pm
8-K
ogfhpnl0xt
4 Aug 22
SpringWorks Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
6:41am